FluChip-8G Influenza A+B Assay

The FluChip-8G Influenza A+B Assay is a multiplex RT-PCR diagnostic tool for qualitatively detecting and differentiating seasonal and certain non-seasonal influenza A subtypes, as well as influenza B lineages, from human respiratory swab samples. It achieves this by amplifying specific viral gene segments, though its performance for non-seasonal A strains was primarily validated with contrived samples and may vary with emerging or unrepresented strains.

The FluChip-8G Influenza A+B Assay is a multiplex RT-PCR in vitro diagnostic test designed for the qualitative detection and differentiation of various influenza viruses from human respiratory specimens. It identifies seasonal influenza A/H3N2, seasonal influenza A/H1N1pdm09, “non-seasonal” influenza A subtypes (other than seasonal H1N1pdm09 or H3N2), and distinguishes between B/Victoria and B/Yamagata genetic lineages of human influenza B viruses. The assay utilizes nucleic acids isolated from nasopharyngeal or nasal swabs from patients exhibiting signs of respiratory infection, amplifying specific gene segments including hemagglutinin (HA), neuraminidase (NA), matrix (M), non-structural (NS), and nucleoprotein (NP) for influenza A, and HA and NA for influenza B. It is not intended for the detection of influenza C viruses. Performance characteristics for detecting seasonal influenza A were established when A/H3N2 was predominant, and for influenza B lineages when B/Victoria was predominant, meaning performance may vary with other emerging strains. Due to the low prevalence of “non-seasonal” influenza A, its detection performance was primarily assessed using contrived samples representing numerous unique strains and subtypes; therefore, actual clinical performance with unrepresented “non-seasonal” strains might differ. Positive results for “non-seasonal” influenza A are presumptive and require confirmation by public health authorities, and negative results do not rule out infection. If a novel influenza A virus is suspected, specific infection control and testing protocols through public health departments are advised.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the assay's performance for detecting 'non-seasonal' influenza A subtypes compare when using actual clinical specimens versus the contrived samples used in the validation?; What is the limit of detection for each specific influenza A and B subtype/lineage targeted by the assay?; How might the assay's performance characteristics change with the emergence of new predominant seasonal influenza A or B strains not prevalent during its validation?; What are the specific gene targets amplified for the M, NS, and NP gene segments for influenza A, and how do these contribute to differentiation beyond HA and NA?; What is the reported cross-reactivity of the assay with other common respiratory viruses or bacterial pathogens?